During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Suzanne Lentzsch, Columbia University, New York, US. We asked, How does the bispecific T-cell engager (BiTE®) AMG 701 compare to other immunotherapies for heavily pretreated patients?
In this video, Lentzsch discusses the first-in-human clinical trial assessing AMG 701, an anti-B-cell maturation antigen BiTE® molecule, in a heavily pretreated relapsed/refractory patient population. She then compares AMG 701 with other immunotherapies and comments that it is too early to give a final verdict on the best antibody.